Shop

NADONA-Renewing-600-x-315

The LTC Patient: Don’t Forget the Liver in this COVID World and Beyond

Free!

1.0 CE

HE In-Service Tool Kit

Description
Chronic liver disease affects over 5.5 million patients in the USA, of whom more than 600,000 have cirrhosis. Its progressive nature is leading to greater prevalence in LTC facilities. Hepatic Encephalopathy (HE) is most common in cirrhosis and subtle signs are observed in nearly 70% of cirrhosis patients and it is a top cause of 30-day hospital readmissions. This patient population is thus highly vulnerable not only to the primary and secondary symptoms of hepatic malfunction, but also to infectious diseases such as the coronavirus pandemic we are experiencing now.This webinar will discuss CDC covid19 strategic recommendations, the impact of covid19 on the liver and AASLD recommendations. This program will also describe the prevalence of hepatic encephalopathy (HE) in LTC residents, its pathophysiology, and its effects on mental state. It will explain the efficacy and safety of lactulose and rifaximin as a mainstay of HE treatment and of alternative treatments available for those patients inadequately responsive to first-line treatment. It will also identify the roles and responsibilities of the LTC interdisciplinary team in diagnosis and treatment of HE in these.

Speaker
Richard Stefanacci,
DO, MGH, MBA, AGSF, CMD
Thomas Jefferson University, Jefferson College of Population Health Geisinger / AtlantiCare Post-Acute Services, PACE, Population Health Medical Director Trinity PACE, Senior Physician

Provided through an unrestricted educational grant from Salix Pharmaceuticals

Category:

Product Description

1.0 CE

HE In-Service Took Kit

Description
Chronic liver disease affects over 5.5 million patients in the USA, of whom more than 600,000 have cirrhosis. Its progressive nature is leading to greater prevalence in LTC facilities. Hepatic Encephalopathy (HE) is most common in cirrhosis and subtle signs are observed in nearly 70% of cirrhosis patients and it is a top cause of 30-day hospital readmissions. This patient population is thus highly vulnerable not only to the primary and secondary symptoms of hepatic malfunction, but also to infectious diseases such as the coronavirus pandemic we are experiencing now.This webinar will discuss CDC covid19 strategic recommendations, the impact of covid19 on the liver and AASLD recommendations. This program will also describe the prevalence of hepatic encephalopathy (HE) in LTC residents, its pathophysiology, and its effects on mental state. It will explain the efficacy and safety of lactulose and rifaximin as a mainstay of HE treatment and of alternative treatments available for those patients inadequately responsive to first-line treatment. It will also identify the roles and responsibilities of the LTC interdisciplinary team in diagnosis and treatment of HE in these.

Speaker
Richard Stefanacci,
DO, MGH, MBA, AGSF, CMD
Thomas Jefferson University, Jefferson College of Population Health Geisinger / AtlantiCare Post-Acute Services, PACE, Population Health Medical Director Trinity PACE, Senior Physician

Provided through an unrestricted educational grant from Salix Pharmaceuticals

 

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

Scroll to top